About Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group, Yuanda Yiyao in Chinese, is an international technology-innovation pharmaceutical group headquartered in Wuhan and listed in Hong Kong (00512.HK), with origins tracing back to 1939. Its official website defines it as an integrated enterprise combining nuclear medicine for oncology diagnosis and treatment, precision cardiovascular intervention technology, pharmaceutical technology and biotechnology.
Its business areas span anti-tumour nuclear medicine with a radioconjugate platform, precision cardiovascular and cerebrovascular intervention, respiratory and critical-care medicines, pharmaceutical raw materials and high-quality amino acids, ophthalmology and ENT products, and an mRNA platform. It reports more than 130 products in development and over 770 R&D staff.
The group maintains a global R&D network with centres in Wuhan's Optics Valley, Boston, Australia, Changzhou, Nanjing, Shanghai and Chengdu. Its scale and its focus on nuclear medicine and interventional devices place it among the most internationalised Chinese pharmaceutical groups of its generation.
Its business areas span anti-tumour nuclear medicine with a radioconjugate platform, precision cardiovascular and cerebrovascular intervention, respiratory and critical-care medicines, pharmaceutical raw materials and high-quality amino acids, ophthalmology and ENT products, and an mRNA platform. It reports more than 130 products in development and over 770 R&D staff.
The group maintains a global R&D network with centres in Wuhan's Optics Valley, Boston, Australia, Changzhou, Nanjing, Shanghai and Chengdu. Its scale and its focus on nuclear medicine and interventional devices place it among the most internationalised Chinese pharmaceutical groups of its generation.